tiprankstipranks
Trending News
More News >
Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO

Aptevo Therapeutics (APVO) Price & Analysis

Compare
542 Followers

APVO Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.60%0.02%0.03%99.34%
0.03% Other Institutional Investors
99.34% Public Companies and Individual Investors

APVO FAQ

What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $4.30 and its highest was $503.28 in the past 12 months.
    What is Aptevo Therapeutics Inc’s market cap?
    Aptevo Therapeutics Inc’s market cap is $3.07M.
      When is Aptevo Therapeutics Inc’s upcoming earnings report date?
      Aptevo Therapeutics Inc’s upcoming earnings report date is Aug 07, 2025 which is in 52 days.
        How were Aptevo Therapeutics Inc’s earnings last quarter?
        Aptevo Therapeutics Inc released its earnings results on May 15, 2025. The company reported -$87.8 earnings per share for the quarter, missing the consensus estimate of -$84.2 by -$3.6.
          Is Aptevo Therapeutics Inc overvalued?
          According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Aptevo Therapeutics Inc pay dividends?
            Aptevo Therapeutics Inc does not currently pay dividends.
            What is Aptevo Therapeutics Inc’s EPS estimate?
            Aptevo Therapeutics Inc’s EPS estimate is -83.2.
              How many shares outstanding does Aptevo Therapeutics Inc have?
              Aptevo Therapeutics Inc has 700,000 shares outstanding.
                What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
                Aptevo Therapeutics Inc reported an EPS of -$87.8 in its last earnings report, missing expectations of -$84.2. Following the earnings report the stock price went same 0%.
                  Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
                  Currently, no hedge funds are holding shares in APVO

                  Company Description

                  Aptevo Therapeutics Inc

                  Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  VivoSim Labs
                  Enveric Biosciences
                  Ensysce Biosciences
                  Revelation Biosciences
                  Synaptogenix
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis